NCT00078546View on ClinicalTrials.gov

EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

January 31, 2007

Study Completion Date

April 30, 2007

Conditions
Nasopharyngeal CancerEBV Infections
Interventions
BIOLOGICAL

EBV specific CTL Infusion

"One injection at one of the following dose levels~Dose level I: 2x107/m2 Dose level II: 5x107/m2 Dose level III: 1x108/m2"

BIOLOGICAL

Anti CD45 monoclonal antibody

400ug/kg over 6 to 8 hr for 4 days

Trial Locations (2)

77030

Texas Children's Hospital, Houston

The Methodist Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00078546 - EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) | Biotech Hunter | Biotech Hunter